MicroRNAs (miRNAs) 
Introduction

Glioblastoma is the most frequently occurring primary malignant brain tumour, with an incidence of 355 new cases per 100,000 Caucasians per year. Despite introduction of modern therapeutic approaches, this cancer remains associated with very poor prognosis characterized by median overall survival less than 1 year [1,2]. For glioblastoma, rapid diffuse and infiltrative growth with high level of cellular heterogeneity associated with therapeutic resistance is typical. There are also multiple genetic alterations characteristic for glioblastoma. Primary glioblastoma arising de novo is often characterized by EGFR amplification and PTEN mutations, whereas TP53 mutations are typical for secondary glioblastoma developing from lower-grade astrocytomas. Nevertheless, this distinction is not absolute and both glioblastoma types may harbour other genetic and chromosomal changes, for example, the loss of heterozygosity (LOH) 10q is the most frequent aberration in both primary and secondary glioblastomas
. miRNAs are small non-coding RNAs, 22- [5] . Afterwards, RNase III enzyme converts pri-miRNAs into pre-miRNAs Within RISC, miRNAs act as specific determinants, whereas protein components achieve target mRNA silencing [6] . Deregulation [10] .
nt in length that guide post-transcriptional gene silencing of their mRNA targets. miRNAs are encoded by genes that are presumably transcribed into long primary miRNAs (pri-miRNAs) by RNA polymerases II/III
Several recent reports have also identified up-regulation of miR-21 in glioblastoma tissue [8, 9] [11, 12] . Oncogenic phenotype indicates also miR-26a, which is highly up-regulated in glioblastoma tissue [8] . Phenomenon of PTEN down-regulation followed by AKT activation was described after transfection of glioblastoma cells with the primary transcript of miR-26a-2. Similarly, the miR-26a mimics decreased PTEN protein levels and increased AKT phosphorylation [13, 14] . Modulation of AKT signalling cascade using miRNAs in glioblastoma cell lines was described also in Nan et (Fig. 2) [26] . [28, 29] . To find potential miRNA mediators of Notch effect in glioma, Kefas et [27] . [30] . when compared to normal human brain [33] . Other studies showed that miR-34a expression was higher in wild-type p53 glioblastoma tissues compared to mutant p53 glioblastoma; miR34a acts as a tumour suppressor in p53-mutant glioma cells U251, partially through regulating SIRT1 [34] . [35] (summarized in Fig. 3 ). [36, 37] . Song [38] (summarized in Fig. 3 ).
C/P ratio represents the range of ratio between tumour samples values (C: centre of the tumour) and the control samples values (P: peripheral brain area from the same patient). L/B ratio represents the ratio between averaged cell line samples values (L) and the control sample values (B); P value is presented (t-test [8], Mann-Whitney U-test [9]). glioma xenograft growth in vivo. This effect was explained by direct regulation of the Bmi-1 mRNA 3Ј-UTR, through a single miR-128 binding site. Bmi-1 expression was significantly up-regulated and miR-128 was down-regulated compared to normal brain. In addition, miR-128 expression leads to a decrease in H3K27 methylation
Notch signalling pathway
Notch signalling is critical in stem cell maintenance and cell survival, as well as in cell fate decisions such as neuronal versus glial fate in the developing nervous system. Therefore, it is not surprising that this pathway plays a key role in brain tumours, including glioblastoma [27]. miR-326 is associated with Notch signalling pathway in glioblastomas. This miRNA was first identified among a set of miRNAs expressed in neurons and further noted on a list of miRNAs elevated in zebrafish embryos treated with a Notch inhibitor
al. performed miRNA microarray analysis of glioma tumour stem cells transfected with Notch-1 siRNA. In these Notch-1 knockdown cells, miR-326 was one of the miRNAs significantly increased when compared to control transfected cells. Therefore, it was indicated that miR-326 is suppressed by Notch activity. However, pre-miR-326 transfection caused substantial decrease in both Notch-1 and Notch-2 protein as was shown by immunoblotting. This paper showed that another Notch pathway components are inhibited by miR-326. It was observed that miR-326 induces apoptosis and decreases glioma cells proliferation, viability and invasiveness of glioblastoma stem cell-like lines. Furthermore, miR-326 transfection also reduced glioma cell tumourigenicity in vivo
Considering that the expression of miR-326 down-regulated the Hedgehog stem cell pathway in medulloblastoma cells, authors tested the effects of this miRNA on Hedgehog activity in a glioma line using the Gli-1 promoter reporter plasmid. Unfortunately, expected effects were not observed in this case; this may reflect distinct roles for miR-326 in these pathways in different cancers
Computational target gene prediction identified pyruvate kinase type M2 (PKM2) as another target of miRNA-326. PKM2 has recently been shown to play a key role in cancer cell metabolism. It is crucial for aerobic glycolysis and provides a growth advantage for tumour cells [31]. To investigate whether PKM2 might be a functionally important target of miR-326, Kefas et al. used RNA interference to knockdown PKM2 expression in glioma cells. Transfection of established glioma and glioma stem cells with PKM2 siRNA reduced their growth, cellular invasion, metabolic activity, ATP and glutathione levels and activated cAMP-activated protein kinase. Levels of PKM2 negatively correlated with levels of miR-326, suggesting regulatory relationship of PKM2 and miR-326 [32]. Among others, all of these results showed that efficient delivery of miR-326 has therapeutic potential against both glioma stem-like cells and established glioma lines. Li et al. studied the role of miR-34a in human brain tumours with a special focus on glioblastomas. They found that miR-34a inhibits Notch-1 and Notch-2 protein expression and 3Ј-UTR reporter activities as well as CDK6 and c-Met protein expression in glioma cells. They observed for the first time that average pre-miR34a expression is down-regulated in human glioblastoma tissues
Fig. 2 MiRNAs involved in TGF-␤ and IFN-␣/IFN-
Transfection of miR-34a into tested glioblastoma cell lines strongly inhibited cell proliferation, cell cycle, cell survival, cell invasion and in vivo glioblastoma xenograft growth; however, the treatment did not affect human astrocyte cell survival and cell cycle. Forced c-Met and Notch-1/2 expression partially rescued the effects of miR-34a on the cell cycle and cell death in gliomas, respectively
NF-B signalling pathway
Nuclear factor-kappa B (NF-B) is the transcription factor with pleiotropic activity owing to its central roles in various biological processes. Aberrant activation of NF-B signalling pathway has been proved to be important for invasiveness and metastatic capacity of tumours through up-regulation of matrix metalloproteinases (MMPs) and transcription factors regulating E-cadherin, such as Snail, Twist or Slug. A critical component in NF-B regulation is the IB kinase (IKK-␤) complex
Single nucleotide polymorphisms and miRNAs: risk factors for glioblastoma
In gliomas, only one polymorphism found in mature miRNA sequence, specifically a polymorphism of miR-196a (rs11614913), has been studied so far. Published data suggest that the CC genotype of miR-196a (rs11614913) [39, 40] , data in glioblastoma showed opposite association between miR-196a genotype and cancer risk. This may be related to the diversity on the tissues origin and characteristic molecular alterations in different cancers [41] .
miRNAs in glioblastoma prognosis and prediction of therapeutic response
Clinical significance of miRNA expression profiles in glioblastoma has not been explored very much. Nevertheless, 16 candidate miRNAs were published to associate with malignant behaviour of gliomas (miR-196a, miR-15b, miR-105, miR-367, miR-184, miR-196b, miR-363, miR-504, miR-302b, miR-128b, miR-601, miR-21, miR-517c, miR-302d, miR-383, miR-135b [43] .
Treatment of malignant gliomas remains one of the greatest challenges facing oncologists today through a frequent resistance to both chemo-and radiotherapeutics and short survival [44] . Considering angiogenesis, which is critical in most solid tumours, including glioblastoma, miR-296 has been demonstrated to be up-regulated in glioblastoma-associated endothelial cells [49] . This miRNA promotes angiogenesis by down-regulating HGS (hepatocyte growth factor-regulated tyrosine kinase substrate), an inhibitor of pro-angiogenic receptors VEGFR2 and PDGFRb (vascular endothelial growth factor and platelet-derived growth factor receptor ␤, respectively). This study indicated the potential of anti-angiogenic therapy of glioblastoma by delivery of a miR-296 inhibitor [49] .
Although siRNAs allow specific knockdown of individual gene targets, miRNAs result in a broad reduction of gene expression being affected. The ability of individual miRNAs to target multiple genes/pathways could be a major advantage, especially given studies indicating the therapeutic necessity of simultaneously targeting multiple pathways in glioblastoma [50] . Unfortunately 
